SCHEMBL6931398

SCHEMBL6931398

CCCc1cccc(C(=O)c2ccccc2)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGB1 P09429 1/20 0.49
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
AKR1C3 P42330 1/20 0.46
GAA P10253 1/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
IAPP P10997 1/20 0.43
BCL2 P10415 1/20 0.42
MCL1 Q07820 1/20 0.42
PRKCI P41743 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27639750 0.91 HMGB1 (0.46) HMGB1MAPTKDM4EALOX15MAPK1
SCHEMBL11525711 0.88 GABRA1 (0.55) HMGB1MAPTKDM4EALOX15MAPK1
SCHEMBL7028825 0.88 HMGB1 (0.51) HMGB1IAPPPRKCICYP3A4CYP2C9
SCHEMBL28823845 0.88 BID (0.54) MAPTKDM4EALOX15HSD17B10PPARG
SCHEMBL7252078 0.86 AKR1C3 (0.52) MAPTAKR1C3GAAPPARGPPARA
SCHEMBL8522548 0.84 AKR1C3 (0.53) HMGB1MAPTKDM4EALOX15MAPK1
SCHEMBL9626492 0.84 AKR1C3 (0.46) MAPTAKR1C3GAAPPARGPPARA
SCHEMBL7598180 0.84 HMGB1 (0.49) HMGB1MAPTKDM4EALOX15MAPK1
SCHEMBL3070365 0.83 CA2 (0.42) HMGB1MAPTKDM4EALOX15MAPK1
SCHEMBL9859 0.83 HMGB1 (0.69) HMGB1KDM4EHSD17B10IAPPMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3600224-B1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2026-05-06 EP claimed
US-12214067-B2 Oil-in-water emulsion sunscreen composition ISP INVESTMENTS INC. (US) 2025-02-04 US claimed
US-20220387290-A1 SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2022-12-08 US claimed
US-20220125701-A1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2022-04-28 US claimed
EP-3946642-A1 SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF ISP Investments LLC (US) 2022-02-09 EP claimed
EP-3600224-B1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2026-05-06 EP disclosed
WO-2026044006-A1 MODIFIED STARCH COMPOUNDS AND USES THEREOF ISP INVESTMENTS LLC (US) 2026-02-26 WO disclosed
EP-4683973-A2 DISPERSANT COMPOSITIONS COMPRISING HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS, AND APPLICATIONS THEREOF ISP Investments LLC (US) 2026-01-28 EP disclosed
US-12497478-B2 High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof ISP INVESTMENTS LLC (US) 2025-12-16 US disclosed
US-20250360066-A1 COMPOSITION COMPRISING A PHOTOCHEMICAL ULTRAVIOLET ABSORBER PRECURSOR AND A COMPOUND FOR INCREASING THEIR PHOTOCHEMICAL CONVERSION RATE ROKA FURADADA S L (ES) 2025-11-27 US disclosed
US-12472207-B2 Anti-inflammatory compositions and methods RR MEDSCIENCES PTY LTD. (AU) 2025-11-18 US disclosed
EP-4604907-A1 A METHOD OF PROVIDING HIGH SPF TO A TOPICAL SURFACE OF A BODY Unilever IP Holdings B.V. (NL) 2025-08-27 EP disclosed
CN-104784057-A Sunscreen compositions WYETH LLC 2015-07-22 CN disclosed
CN-102573766-B Sunscreen compositions WYETH LLC 2015-05-27 CN disclosed
CN-103596542-A Clear wet sprays and gels ISP INVESTMENTS INC 2014-02-19 CN disclosed
CN-102573766-A Sunscreen compositions WYETH LLC 2012-07-11 CN disclosed
EP-0888278-B1 ANTIDIABETIC AGENTS MERCK & CO INC (US) 2003-07-23 EP disclosed
EP-0888278-A4 ANTIDIABETIC AGENTS MERCK & CO INC (US) 1999-06-30 EP disclosed
EP-0888278-A1 ANTIDIABETIC AGENTS Merck & Co., Inc. (US) 1999-01-07 EP disclosed
WO-1997028115-A1 ANTIDIABETIC AGENTS MERCK & CO., INC. (US) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497478-B2 High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof MRPL9, PRMT9, MRPL19 HMGB1 45/4885MAPT 3882/4885KDM4E 2470/4885
US-20250360066-A1 COMPOSITION COMPRISING A PHOTOCHEMICAL ULTRAVIOLET ABSORBER PRECURSOR AND A COMPOUND FOR INCREASING THEIR PHOTOCHEMICAL CONVERSION RATE TYR, PAH, ERCC4 HMGB1 3900/4885MAPT 387/4885KDM4E 2920/4885
US-12472207-B2 Anti-inflammatory compositions and methods SOD3, MPO, SOD1 HMGB1 90/4885MAPT 3741/4885KDM4E 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.